ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

NEXT STORY
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
PREV STORY
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer

HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 and One or More Comorbidity

author_avatar
NASDAQ Market News

The Middle East & Africa RNAi therapeutics market is expected to reach US$ 29.02 million by 2027 from US$ 16.76 million in 2019

author_avatar
NASDAQ Market News